These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27179610)

  • 1. Analysing pseudoephedrine/methamphetamine policy options in Australia using multi-criteria decision modelling.
    Manning M; Wong GT; Ransley J; Smith C
    Int J Drug Policy; 2016 Jun; 32():85-92. PubMed ID: 27179610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing community pharmacist engagement in a policing partnership strategy to reduce the illicit diversion of pseudoephedrine products.
    Webster JL
    Res Social Adm Pharm; 2013; 9(6):903-17. PubMed ID: 23548589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of pseudoephedrine regulation at Australian pharmacies through Project Stop: A narrative review.
    Brookfield S; Gartner C
    Drug Alcohol Rev; 2024 Jan; 43(1):325-342. PubMed ID: 37963493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The advent of a new pseudoephedrine product to combat methamphetamine abuse.
    Brzeczko AW; Leech R; Stark JG
    Am J Drug Alcohol Abuse; 2013 Sep; 39(5):284-90. PubMed ID: 23968171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical sales of pseudoephedrine: the impact of electronic tracking systems on methamphetamine crime incidents.
    Mazerolle L; McGuffog I; Ferris J; Chamlin MB
    Addiction; 2017 Mar; 112(3):468-474. PubMed ID: 27741563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of methamphetamine precursor chemical legislation, a suppression policy, on the demand for drug treatment.
    Cunningham JK; Liu LM
    Soc Sci Med; 2008 Apr; 66(7):1463-73. PubMed ID: 18222587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal methamphetamine smoking among regular ecstasy users in Australia: increases in use and associations with harm.
    Kinner SA; Degenhardt L
    Drug Alcohol Rev; 2008 May; 27(3):292-300. PubMed ID: 18368611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007.
    Maxwell JC; Rutkowski BA
    Drug Alcohol Rev; 2008 May; 27(3):229-35. PubMed ID: 18368603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mexico's methamphetamine precursor chemical interventions: impacts on drug treatment admissions.
    Cunningham JK; Bojorquez I; Campollo O; Liu LM; Maxwell JC
    Addiction; 2010 Nov; 105(11):1973-83. PubMed ID: 20707864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epidemiology of methamphetamine use and harm in Australia.
    Degenhardt L; Roxburgh A; Black E; Bruno R; Campbell G; Kinner S; Fetherston J
    Drug Alcohol Rev; 2008 May; 27(3):243-52. PubMed ID: 18368605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential/precursor chemicals and drug consumption: impacts of US sodium permanganate and Mexico pseudoephedrine controls on the numbers of US cocaine and methamphetamine users.
    Cunningham JK; Liu LM; Callaghan RC
    Addiction; 2016 Nov; 111(11):1999-2009. PubMed ID: 27529812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of methamphetamine precursor regulations.
    McKetin R; Sutherland R; Bright DA; Norberg MM
    Addiction; 2011 Nov; 106(11):1911-24. PubMed ID: 21895829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of controlling pseudoephedrine availability on methamphetamine-related emergency department visits.
    Hendrickson RG; Cloutier RL; Fu R
    Acad Emerg Med; 2010 Nov; 17(11):1216-22. PubMed ID: 21175520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystalline methamphetamine use and methamphetamine-related harms in Australia.
    Degenhardt L; Sara G; McKetin R; Roxburgh A; Dobbins T; Farrell M; Burns L; Hall WD
    Drug Alcohol Rev; 2017 Mar; 36(2):160-170. PubMed ID: 27286742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enacting multiple methamphetamines: the ontological politics of public discourse and consumer accounts of a drug and its effects.
    Dwyer R; Moore D
    Int J Drug Policy; 2013 May; 24(3):203-11. PubMed ID: 23540297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methamphetamine use among gay and bisexual men in Australia: Trends in recent and regular use from the Gay Community Periodic Surveys.
    Lea T; Mao L; Hopwood M; Prestage G; Zablotska I; de Wit J; Holt M
    Int J Drug Policy; 2016 Mar; 29():66-72. PubMed ID: 26851066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Counterpublic health and the design of drug services for methamphetamine consumers in Melbourne.
    Duff C; Moore D
    Health (London); 2015 Jan; 19(1):51-66. PubMed ID: 24948593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying the societal cost of methamphetamine use to Australia.
    Tait RJ; Whetton S; Shanahan M; Cartwright K; Ferrante A; Gray D; Kaye S; McKetin R; Pidd K; Ritter A; Roche A; Allsop S
    Int J Drug Policy; 2018 Dec; 62():30-36. PubMed ID: 30352332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methamphetamine use among Australian workers and its implications for prevention.
    Roche AM; Pidd K; Bywood P; Freeman T
    Drug Alcohol Rev; 2008 May; 27(3):334-41. PubMed ID: 18368616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing environmental prevention strategies for reducing the prevalence and associated harms of methamphetamine use.
    Yacoubian GS
    J Drug Educ; 2007; 37(1):31-53. PubMed ID: 17982934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.